サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1239519

群発頭痛市場：タイプ別、薬物クラス別、流通チャネル別：世界の機会分析と産業予測、2021-2031年

Cluster Headache Market By Type, By Drug class, By Distribution channel : Global Opportunity Analysis and Industry Forecast, 2021-2031
出版日: | 発行: Allied Market Research | ページ情報: 英文 233 Pages | 納期: 2～3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
群発頭痛市場：タイプ別、薬物クラス別、流通チャネル別：世界の機会分析と産業予測、2021-2031年
出版日: 2023年01月01日
発行: Allied Market Research
ページ情報: 英文 233 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

群発頭痛の市場規模は2021年に3億5,600万米ドル、2031年には5億2,298万米ドルに達すると推定され、2022年から2031年にかけて3.9%のCAGRを示しました。

群発頭痛は、三叉神経自律神経セファルギー（TACs）として知られる一次性頭痛の中で最も一般的なタイプです。群発頭痛は、15～180分続く非常に激しい片側性頭痛の発作が、1日に数回まで起こることが特徴です。痛みの激しさ、発作の長さ、流涙や結膜充血などの脳神経系自律神経症状の有無で区別されます。発作はしばしば群発し、一度に数週間から数ヶ月にわたって連続して起こり、その後、完全に寛解する時期があります。この重大な痛みは、特に群発期間中に自殺傾向の増加を伴います。

群発頭痛市場の促進要因は、群発頭痛に苦しむ患者数の増加、群発頭痛の有効な治療薬開拓のための投資の増加です。また、群発頭痛などの神経疾患の発生件数の急増により、頭痛疾患の治療に有効な薬剤の需要が高まっており、群発頭痛の発生件数の増加が市場の成長を促進すると予想されます。例えば、SAGE Journal-Cephalalgia 2022に掲載された論文によると、ノルウェーにおける群発頭痛の有病率は10万人/年あたり48.6人であることが判明し、市場の成長を牽引していると述べています。また、今後数年間で規制当局の承認を受けると予想される群発頭痛の治療薬のパイプラインが増加し、市場の拡大を促進すると予測されます。

さらに、群発頭痛などの頭痛疾患に関する研究開発活動に対して、政府や民間機関からさまざまな助成金や奨学金が提供されており、これが市場拡大のさらなる推進力となっています。例えば、国際頭痛学会（IHS）2022の報告書によると、IHSは若手研究者の革新的でインパクトのある研究を支援し、頭痛分野における若手研究者のキャリアを促進し、頭痛疾患の知識ベースを増やすために「IHS Junior Research Grant」など合計20～30の研究助成金を提供しており、頭痛疾患の研究開発に利用できるこうした研究助成金は市場の成長を促進すると予想されています。

しかし、医薬品承認に時間がかかり、規制が厳しいことが、市場の成長を抑制する要因となっています。また、有利な償還政策がないことも、市場の成長を抑制する要因になると予想されます。

さらに、生物学的製剤などの新規治療薬に対する需要の増加、治療法に関する意識の向上、安全で有効な群発頭痛治療薬を開発するための研究開発の増加は、群発頭痛市場の主要プレイヤーに有利な機会を提供します。

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 市場概要

  • 市場の定義と範囲
  • 主な調査結果
    • 主な影響要因
    • 主な投資ポケット
  • ポーターのファイブフォース分析
    • 供給企業の交渉力
    • 買い手の交渉力
    • 代替品の脅威
    • 新規参入業者の脅威
    • 適度な競争の激しさ
  • 市場力学
    • 促進要因
      • 群発頭痛の有病率の上昇
      • 群発頭痛の新規治療薬の開発
      • 群発頭痛に対する意識の高まり
    • 抑制要因
      • 群発頭痛に使われる薬の副作用
    • 機会
      • 新興市場における成長機会
  • 市場におけるCOVID-19影響分析

第4章 群発頭痛市場：タイプ別

  • 概要
    • 市場規模と予測
  • 反復発作性
    • 主要な市場動向、成長要因と機会
    • 市場規模と予測：地域別
    • 市場シェア分析： 国別
  • 慢性
    • 主要な市場動向、成長要因と機会
    • 市場規模と予測：地域別
    • 市場シェア分析： 国別

第5章 群発頭痛市場：薬物クラス別

  • 概要
    • 市場規模と予測
  • 麦角誘導体
    • 主要な市場動向、成長要因と機会
    • 市場規模と予測：地域別
    • 市場シェア分析： 国別
  • カルシウムチャネル遮断薬
    • 主要な市場動向、成長要因と機会
    • 市場規模と予測：地域別
    • 市場シェア分析： 国別
  • トリプタン
    • 主要な市場動向、成長要因と機会
    • 市場規模と予測：地域別
    • 市場シェア分析： 国別
  • その他
    • 主要な市場動向、成長要因と機会
    • 市場規模と予測：地域別
    • 市場シェア分析： 国別

第6章 群発頭痛市場：流通チャネル別

  • 概要
    • 市場規模と予測
  • 病院薬局
    • 主要な市場動向、成長要因と機会
    • 市場規模と予測：地域別
    • 市場シェア分析： 国別
  • ドラッグストアおよび小売薬局
    • 主要な市場動向、成長要因と機会
    • 市場規模と予測：地域別
    • 市場シェア分析： 国別
  • その他
    • 主要な市場動向、成長要因と機会
    • 市場規模と予測：地域別
    • 市場シェア分析： 国別

第7章 群発頭痛市場：地域別

  • 概要
    • 市場規模と予測：地域別
  • 北米
    • 主な動向と機会
    • 市場規模と予測：タイプ別
    • 市場規模と予測：薬物クラス別
    • 市場規模と予測：流通チャネル別
    • 市場規模と予測：国別
      • 米国
      • 主要な市場動向、成長要因と機会
      • 市場規模と予測：タイプ別
      • 市場規模と予測：薬物クラス別
      • 市場規模と予測：流通チャネル別
      • カナダ
      • 主要な市場動向、成長要因と機会
      • 市場規模と予測：タイプ別
      • 市場規模と予測：薬物クラス別
      • 市場規模と予測：流通チャネル別
      • メキシコ
      • 主要な市場動向、成長要因と機会
      • 市場規模と予測：タイプ別
      • 市場規模と予測：薬物クラス別
      • 市場規模と予測：流通チャネル別
  • 欧州
    • 主な動向と機会
    • 市場規模と予測：タイプ別
    • 市場規模と予測：薬物クラス別
    • 市場規模と予測：流通チャネル別
    • 市場規模と予測：国別
      • ドイツ
      • 主要な市場動向、成長要因と機会
      • 市場規模と予測：タイプ別
      • 市場規模と予測：薬物クラス別
      • 市場規模と予測：流通チャネル別
      • フランス
      • 主要な市場動向、成長要因と機会
      • 市場規模と予測：タイプ別
      • 市場規模と予測：薬物クラス別
      • 市場規模と予測：流通チャネル別
      • 英国
      • 主要な市場動向、成長要因と機会
      • 市場規模と予測：タイプ別
      • 市場規模と予測：薬物クラス別
      • 市場規模と予測：流通チャネル別
      • イタリア
      • 主要な市場動向、成長要因と機会
      • 市場規模と予測：タイプ別
      • 市場規模と予測：薬物クラス別
      • 市場規模と予測：流通チャネル別
      • スペイン
      • 主要な市場動向、成長要因と機会
      • 市場規模と予測：タイプ別
      • 市場規模と予測：薬物クラス別
      • 市場規模と予測：流通チャネル別
      • その他欧州
      • 主要な市場動向、成長要因と機会
      • 市場規模と予測：タイプ別
      • 市場規模と予測：薬物クラス別
      • 市場規模と予測：流通チャネル別
  • アジア太平洋
    • 主な動向と機会
    • 市場規模と予測：タイプ別
    • 市場規模と予測：薬物クラス別
    • 市場規模と予測：流通チャネル別
    • 市場規模と予測：国別
      • 日本
      • 主要な市場動向、成長要因と機会
      • 市場規模と予測：タイプ別
      • 市場規模と予測：薬物クラス別
      • 市場規模と予測：流通チャネル別
      • 中国
      • 主要な市場動向、成長要因と機会
      • 市場規模と予測：タイプ別
      • 市場規模と予測：薬物クラス別
      • 市場規模と予測：流通チャネル別
      • インド
      • 主要な市場動向、成長要因と機会
      • 市場規模と予測：タイプ別
      • 市場規模と予測：薬物クラス別
      • 市場規模と予測：流通チャネル別
      • オーストラリア
      • 主要な市場動向、成長要因と機会
      • 市場規模と予測：タイプ別
      • 市場規模と予測：薬物クラス別
      • 市場規模と予測：流通チャネル別
      • 韓国
      • 主要な市場動向、成長要因と機会
      • 市場規模と予測：タイプ別
      • 市場規模と予測：薬物クラス別
      • 市場規模と予測：流通チャネル別
      • その他アジア太平洋地域
      • 主要な市場動向、成長要因と機会
      • 市場規模と予測：タイプ別
      • 市場規模と予測：薬物クラス別
      • 市場規模と予測：流通チャネル別
  • ラテンアメリカ・中東・アフリカ
    • 主な動向と機会
    • 市場規模と予測：タイプ別
    • 市場規模と予測：薬物クラス別
    • 市場規模と予測：流通チャネル別
    • 市場規模と予測：国別
      • ブラジル
      • 主要な市場動向、成長要因と機会
      • 市場規模と予測：タイプ別
      • 市場規模と予測：薬物クラス別
      • 市場規模と予測：流通チャネル別
      • サウジアラビア
      • 主要な市場動向、成長要因と機会
      • 市場規模と予測：タイプ別
      • 市場規模と予測：薬物クラス別
      • 市場規模と予測：流通チャネル別
      • 南アフリカ
      • 主要な市場動向、成長要因と機会
      • 市場規模と予測：タイプ別
      • 市場規模と予測：薬物クラス別
      • 市場規模と予測：流通チャネル別
      • その他のラテンアメリカ・中東・アフリカ
      • 主要な市場動向、成長要因と機会
      • 市場規模と予測：タイプ別
      • 市場規模と予測：薬物クラス別
      • 市場規模と予測：流通チャネル別

第8章 競合情勢

  • イントロダクション
  • 主要成功戦略
  • トップ 10プレーヤーの製品マッピング
  • 競合ダッシュボード
  • 競合ヒートマップ
  • トッププレーヤーのポジショニング、2021

第9章 企業プロファイル

  • Dr. Reddy's Laboratories Ltd.
  • Eli Lilly and Company
  • FRESENIUS SE & Co. KGaA（Fresenius Kabi）
  • GlaxoSmithKline plc
  • Novartis AG
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Arrotex Australia Group
  • Grunenthal
図表

LIST OF TABLES

  • TABLE 01. GLOBAL CLUSTER HEADACHE MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 02. CLUSTER HEADACHE MARKET FOR EPISODIC, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 03. CLUSTER HEADACHE MARKET FOR CHRONIC, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 04. GLOBAL CLUSTER HEADACHE MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 05. CLUSTER HEADACHE MARKET FOR ERGOT DERIVATIVES, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 06. CLUSTER HEADACHE MARKET FOR CALCIUM CHANNEL BLOCKERS, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 07. CLUSTER HEADACHE MARKET FOR TRIPTANS, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 08. CLUSTER HEADACHE MARKET FOR OTHERS, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 09. GLOBAL CLUSTER HEADACHE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 10. CLUSTER HEADACHE MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 11. CLUSTER HEADACHE MARKET FOR DRUG STORES AND RETAIL PHARMACIES, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 12. CLUSTER HEADACHE MARKET FOR OTHERS, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 13. CLUSTER HEADACHE MARKET, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 14. NORTH AMERICA CLUSTER HEADACHE MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 15. NORTH AMERICA CLUSTER HEADACHE MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 16. NORTH AMERICA CLUSTER HEADACHE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 17. NORTH AMERICA CLUSTER HEADACHE MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 18. U.S. CLUSTER HEADACHE MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 19. U.S. CLUSTER HEADACHE MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 20. U.S. CLUSTER HEADACHE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 21. CANADA CLUSTER HEADACHE MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 22. CANADA CLUSTER HEADACHE MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 23. CANADA CLUSTER HEADACHE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 24. MEXICO CLUSTER HEADACHE MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 25. MEXICO CLUSTER HEADACHE MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 26. MEXICO CLUSTER HEADACHE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 27. EUROPE CLUSTER HEADACHE MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 28. EUROPE CLUSTER HEADACHE MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 29. EUROPE CLUSTER HEADACHE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 30. EUROPE CLUSTER HEADACHE MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 31. GERMANY CLUSTER HEADACHE MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 32. GERMANY CLUSTER HEADACHE MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 33. GERMANY CLUSTER HEADACHE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 34. FRANCE CLUSTER HEADACHE MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 35. FRANCE CLUSTER HEADACHE MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 36. FRANCE CLUSTER HEADACHE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 37. UK CLUSTER HEADACHE MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 38. UK CLUSTER HEADACHE MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 39. UK CLUSTER HEADACHE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 40. ITALY CLUSTER HEADACHE MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 41. ITALY CLUSTER HEADACHE MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 42. ITALY CLUSTER HEADACHE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 43. SPAIN CLUSTER HEADACHE MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 44. SPAIN CLUSTER HEADACHE MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 45. SPAIN CLUSTER HEADACHE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 46. REST OF EUROPE CLUSTER HEADACHE MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 47. REST OF EUROPE CLUSTER HEADACHE MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 48. REST OF EUROPE CLUSTER HEADACHE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 49. ASIA-PACIFIC CLUSTER HEADACHE MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 50. ASIA-PACIFIC CLUSTER HEADACHE MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 51. ASIA-PACIFIC CLUSTER HEADACHE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 52. ASIA-PACIFIC CLUSTER HEADACHE MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 53. JAPAN CLUSTER HEADACHE MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 54. JAPAN CLUSTER HEADACHE MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 55. JAPAN CLUSTER HEADACHE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 56. CHINA CLUSTER HEADACHE MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 57. CHINA CLUSTER HEADACHE MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 58. CHINA CLUSTER HEADACHE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 59. INDIA CLUSTER HEADACHE MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 60. INDIA CLUSTER HEADACHE MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 61. INDIA CLUSTER HEADACHE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 62. AUSTRALIA CLUSTER HEADACHE MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 63. AUSTRALIA CLUSTER HEADACHE MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 64. AUSTRALIA CLUSTER HEADACHE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 65. SOUTH KOREA CLUSTER HEADACHE MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 66. SOUTH KOREA CLUSTER HEADACHE MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 67. SOUTH KOREA CLUSTER HEADACHE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 68. REST OF ASIA-PACIFIC CLUSTER HEADACHE MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 69. REST OF ASIA-PACIFIC CLUSTER HEADACHE MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 70. REST OF ASIA-PACIFIC CLUSTER HEADACHE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 71. LAMEA CLUSTER HEADACHE MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 72. LAMEA CLUSTER HEADACHE MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 73. LAMEA CLUSTER HEADACHE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 74. LAMEA CLUSTER HEADACHE MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 75. BRAZIL CLUSTER HEADACHE MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 76. BRAZIL CLUSTER HEADACHE MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 77. BRAZIL CLUSTER HEADACHE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 78. SAUDI ARABIA CLUSTER HEADACHE MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 79. SAUDI ARABIA CLUSTER HEADACHE MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 80. SAUDI ARABIA CLUSTER HEADACHE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 81. SOUTH AFRICA CLUSTER HEADACHE MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 82. SOUTH AFRICA CLUSTER HEADACHE MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 83. SOUTH AFRICA CLUSTER HEADACHE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 84. REST OF LAMEA CLUSTER HEADACHE MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 85. REST OF LAMEA CLUSTER HEADACHE MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 86. REST OF LAMEA CLUSTER HEADACHE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 87. DR. REDDY'S LABORATORIES LTD.: KEY EXECUTIVES
  • TABLE 88. DR. REDDY'S LABORATORIES LTD.: COMPANY SNAPSHOT
  • TABLE 89. DR. REDDY'S LABORATORIES LTD.: PRODUCT SEGMENTS
  • TABLE 90. DR. REDDY'S LABORATORIES LTD.: PRODUCT PORTFOLIO
  • TABLE 91. ELI LILLY AND COMPANY: KEY EXECUTIVES
  • TABLE 92. ELI LILLY AND COMPANY: COMPANY SNAPSHOT
  • TABLE 93. ELI LILLY AND COMPANY: PRODUCT SEGMENTS
  • TABLE 94. ELI LILLY AND COMPANY: PRODUCT PORTFOLIO
  • TABLE 95. ELI LILLY AND COMPANY: KEY STRATERGIES
  • TABLE 96. FRESENIUS SE & CO. KGAA (FRESENIUS KABI): KEY EXECUTIVES
  • TABLE 97. FRESENIUS SE & CO. KGAA (FRESENIUS KABI): COMPANY SNAPSHOT
  • TABLE 98. FRESENIUS SE & CO. KGAA (FRESENIUS KABI): PRODUCT SEGMENTS
  • TABLE 99. FRESENIUS SE & CO. KGAA (FRESENIUS KABI): PRODUCT PORTFOLIO
  • TABLE 100. GLAXOSMITHKLINE PLC: KEY EXECUTIVES
  • TABLE 101. GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT
  • TABLE 102. GLAXOSMITHKLINE PLC: PRODUCT SEGMENTS
  • TABLE 103. GLAXOSMITHKLINE PLC: PRODUCT PORTFOLIO
  • TABLE 104. NOVARTIS AG: KEY EXECUTIVES
  • TABLE 105. NOVARTIS AG: COMPANY SNAPSHOT
  • TABLE 106. NOVARTIS AG: PRODUCT SEGMENTS
  • TABLE 107. NOVARTIS AG: PRODUCT PORTFOLIO
  • TABLE 108. PFIZER INC.: KEY EXECUTIVES
  • TABLE 109. PFIZER INC.: COMPANY SNAPSHOT
  • TABLE 110. PFIZER INC.: PRODUCT SEGMENTS
  • TABLE 111. PFIZER INC.: PRODUCT PORTFOLIO
  • TABLE 112. SUN PHARMACEUTICAL INDUSTRIES LTD.: KEY EXECUTIVES
  • TABLE 113. SUN PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
  • TABLE 114. SUN PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT SEGMENTS
  • TABLE 115. SUN PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO
  • TABLE 116. TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY EXECUTIVES
  • TABLE 117. TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
  • TABLE 118. TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT SEGMENTS
  • TABLE 119. TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO
  • TABLE 120. ARROTEX AUSTRALIA GROUP: KEY EXECUTIVES
  • TABLE 121. ARROTEX AUSTRALIA GROUP: COMPANY SNAPSHOT
  • TABLE 122. ARROTEX AUSTRALIA GROUP: PRODUCT SEGMENTS
  • TABLE 123. ARROTEX AUSTRALIA GROUP: PRODUCT PORTFOLIO
  • TABLE 124. ARROTEX AUSTRALIA GROUP: KEY STRATERGIES
  • TABLE 125. GRUNENTHAL: KEY EXECUTIVES
  • TABLE 126. GRUNENTHAL: COMPANY SNAPSHOT
  • TABLE 127. GRUNENTHAL: PRODUCT SEGMENTS
  • TABLE 128. GRUNENTHAL: PRODUCT PORTFOLIO

LIST OF FIGURES

  • FIGURE 01. CLUSTER HEADACHE MARKET, 2021-2031
  • FIGURE 02. SEGMENTATION OF CLUSTER HEADACHE MARKET, 2021-2031
  • FIGURE 03. TOP INVESTMENT POCKETS IN CLUSTER HEADACHE MARKET (2022-2031)
  • FIGURE 04. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 05. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 06. MODERATE THREAT OF SUBSTITUTES
  • FIGURE 07. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 08. MODERATE INTENSITY OF RIVALRY
  • FIGURE 09. DRIVERS, RESTRAINTS AND OPPORTUNITIES: GLOBALCLUSTER HEADACHE MARKET
  • FIGURE 10. CLUSTER HEADACHE MARKET, BY TYPE, 2021(%)
  • FIGURE 11. COMPARATIVE SHARE ANALYSIS OF CLUSTER HEADACHE MARKET FOR EPISODIC, BY COUNTRY 2021-2031(%)
  • FIGURE 12. COMPARATIVE SHARE ANALYSIS OF CLUSTER HEADACHE MARKET FOR CHRONIC, BY COUNTRY 2021-2031(%)
  • FIGURE 13. CLUSTER HEADACHE MARKET, BY DRUG CLASS, 2021(%)
  • FIGURE 14. COMPARATIVE SHARE ANALYSIS OF CLUSTER HEADACHE MARKET FOR ERGOT DERIVATIVES, BY COUNTRY 2021-2031(%)
  • FIGURE 15. COMPARATIVE SHARE ANALYSIS OF CLUSTER HEADACHE MARKET FOR CALCIUM CHANNEL BLOCKERS, BY COUNTRY 2021-2031(%)
  • FIGURE 16. COMPARATIVE SHARE ANALYSIS OF CLUSTER HEADACHE MARKET FOR TRIPTANS, BY COUNTRY 2021-2031(%)
  • FIGURE 17. COMPARATIVE SHARE ANALYSIS OF CLUSTER HEADACHE MARKET FOR OTHERS, BY COUNTRY 2021-2031(%)
  • FIGURE 18. CLUSTER HEADACHE MARKET, BY DISTRIBUTION CHANNEL, 2021(%)
  • FIGURE 19. COMPARATIVE SHARE ANALYSIS OF CLUSTER HEADACHE MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY 2021-2031(%)
  • FIGURE 20. COMPARATIVE SHARE ANALYSIS OF CLUSTER HEADACHE MARKET FOR DRUG STORES AND RETAIL PHARMACIES, BY COUNTRY 2021-2031(%)
  • FIGURE 21. COMPARATIVE SHARE ANALYSIS OF CLUSTER HEADACHE MARKET FOR OTHERS, BY COUNTRY 2021-2031(%)
  • FIGURE 22. CLUSTER HEADACHE MARKET BY REGION, 2021
  • FIGURE 23. U.S. CLUSTER HEADACHE MARKET, 2021-2031 ($MILLION)
  • FIGURE 24. CANADA CLUSTER HEADACHE MARKET, 2021-2031 ($MILLION)
  • FIGURE 25. MEXICO CLUSTER HEADACHE MARKET, 2021-2031 ($MILLION)
  • FIGURE 26. GERMANY CLUSTER HEADACHE MARKET, 2021-2031 ($MILLION)
  • FIGURE 27. FRANCE CLUSTER HEADACHE MARKET, 2021-2031 ($MILLION)
  • FIGURE 28. UK CLUSTER HEADACHE MARKET, 2021-2031 ($MILLION)
  • FIGURE 29. ITALY CLUSTER HEADACHE MARKET, 2021-2031 ($MILLION)
  • FIGURE 30. SPAIN CLUSTER HEADACHE MARKET, 2021-2031 ($MILLION)
  • FIGURE 31. REST OF EUROPE CLUSTER HEADACHE MARKET, 2021-2031 ($MILLION)
  • FIGURE 32. JAPAN CLUSTER HEADACHE MARKET, 2021-2031 ($MILLION)
  • FIGURE 33. CHINA CLUSTER HEADACHE MARKET, 2021-2031 ($MILLION)
  • FIGURE 34. INDIA CLUSTER HEADACHE MARKET, 2021-2031 ($MILLION)
  • FIGURE 35. AUSTRALIA CLUSTER HEADACHE MARKET, 2021-2031 ($MILLION)
  • FIGURE 36. SOUTH KOREA CLUSTER HEADACHE MARKET, 2021-2031 ($MILLION)
  • FIGURE 37. REST OF ASIA-PACIFIC CLUSTER HEADACHE MARKET, 2021-2031 ($MILLION)
  • FIGURE 38. BRAZIL CLUSTER HEADACHE MARKET, 2021-2031 ($MILLION)
  • FIGURE 39. SAUDI ARABIA CLUSTER HEADACHE MARKET, 2021-2031 ($MILLION)
  • FIGURE 40. SOUTH AFRICA CLUSTER HEADACHE MARKET, 2021-2031 ($MILLION)
  • FIGURE 41. REST OF LAMEA CLUSTER HEADACHE MARKET, 2021-2031 ($MILLION)
  • FIGURE 42. TOP WINNING STRATEGIES, BY YEAR
  • FIGURE 43. TOP WINNING STRATEGIES, BY DEVELOPMENT
  • FIGURE 44. TOP WINNING STRATEGIES, BY COMPANY
  • FIGURE 45. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 46. COMPETITIVE DASHBOARD
  • FIGURE 47. COMPETITIVE HEATMAP: CLUSTER HEADACHE MARKET
  • FIGURE 48. TOP PLAYER POSITIONING, 2021
  • FIGURE 49. DR. REDDY'S LABORATORIES LTD.: NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 50. DR. REDDY'S LABORATORIES LTD.: REVENUE SHARE BY SEGMENT, 2021 (%)
  • FIGURE 51. DR. REDDY'S LABORATORIES LTD.: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 52. ELI LILLY AND COMPANY: NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 53. ELI LILLY AND COMPANY: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 54. FRESENIUS SE & CO. KGAA (FRESENIUS KABI): NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 55. FRESENIUS SE & CO. KGAA (FRESENIUS KABI): REVENUE SHARE BY SEGMENT, 2021 (%)
  • FIGURE 56. FRESENIUS SE & CO. KGAA (FRESENIUS KABI): REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 57. GLAXOSMITHKLINE PLC: NET SALES, 2019-2021 ($MILLION)
  • FIGURE 58. GLAXOSMITHKLINE PLC: REVENUE SHARE BY SEGMENT, 2021 (%)
  • FIGURE 59. GLAXOSMITHKLINE PLC: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 60. NOVARTIS AG: NET SALES, 2019-2021 ($MILLION)
  • FIGURE 61. NOVARTIS AG: REVENUE SHARE BY SEGMENT, 2021 (%)
  • FIGURE 62. NOVARTIS AG: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 63. PFIZER INC.: NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 64. PFIZER INC.: REVENUE SHARE BY SEGMENT, 2021 (%)
  • FIGURE 65. PFIZER INC.: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 66. SUN PHARMACEUTICAL INDUSTRIES LTD.: NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 67. SUN PHARMACEUTICAL INDUSTRIES LTD.: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 68. TEVA PHARMACEUTICAL INDUSTRIES LTD.: NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 69. TEVA PHARMACEUTICAL INDUSTRIES LTD.: REVENUE SHARE BY SEGMENT, 2021 (%)
  • FIGURE 70. GRUNENTHAL: NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 71. GRUNENTHAL: REVENUE SHARE BY SEGMENT, 2021 (%)
  • FIGURE 72. GRUNENTHAL: REVENUE SHARE BY REGION, 2021 (%)
目次
Product Code: A14443

The cluster headache market size valued for $356.00 million in 2021 and is estimated to reach $522.98 million by 2031, exhibiting a CAGR of 3.9% from 2022 to 2031.  

Cluster headache is the most common type of the primary headache known as trigeminal autonomic cephalgia (TACs). Cluster headache is characterized by attacks of very severe, unilateral headache lasting 15-180 minutes, up to several times per day. It is distinguished by the severe nature of the pain, length of attacks, and presence of cranial autonomic symptoms such as lacrimation and conjunctival injection. Attacks often cluster and can occur in series for weeks or months at a time, followed by a period of complete remission. This significant pain is accompanied by increased suicidality during cluster periods, particularly during the time of the headache.   

The driving factors for cluster headache market are increase in number of patients suffering from cluster headache, and rise in investments for development of effective medications for cluster headache.  Moreover, surge in incidences of neurological disorders such as cluster headache results in demand of effective medications for treating headache disorders, thus increasing incidences of cluster headache is expected to drive the growth of the market. For instance, according to article published in SAGE Journal - Cephalalgia 2022, stated that, prevalence of cluster headache in Norway was found to be 48.6 per 100,000/year, thereby driving the growth of the market. In addition, increase in number of pipeline medications for treating cluster headache that is anticipated to receive regulatory approval in the upcoming years is projected to propel market expansion.     

Further, various grants and fellowships are provided by government and private institutions for research and development activities involving headache disorders such as cluster headache, which further propels the market expansion. For instance, according to report of International Headache Society (IHS) 2022, stated that, IHS offers total 20-30 fellowships such as 'IHS Junior Research Grant' to support innovative and impactful research from young investigators, promote the career of young investigators in the field of headache and increase the knowledge base of headache disorders, thus such available fellowships for R&D in headache disorders is anticipated to drive the growth of the market.    

However, lengthy drug approval process and strict regulatory pathways are the factors that restrain the growth of the market. In addition, absence of favorable reimbursement policies is also expected to constrain the growth of the market.   

Further, rise in demand for novel therapies such as biologics, increase in awareness about treatment options and increase in R&D to develop safe and efficacious drugs for cluster headache treatment offer lucrative opportunities to key players of the cluster headache market.  

The cluster headache market is segmented into type, drug class, distribution channel and region. By type, the market is categorized into episodic and chronic. By drug class, the market is categorized into ergot derivatives, calcium channel blockers, triptans, and others. By distribution channel, the market is categorized into hospital pharmacies, online providers and drug stores and retail pharmacies. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).  

Major Key players that operate in the global cluster headache market are Arrotex Australia Group, AstraZeneca, Dr. Reddy's Laboratories Ltd., Eli Lilly and Company, Fresenius SE & Co. KGaA, GlaxoSmithKline plc, Novartis AG, Pfizer Inc., Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd.  

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the cluster headache market analysis from 2021 to 2031 to identify the prevailing cluster headache market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the cluster headache market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global cluster headache market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Drug class

  • Ergot derivatives
  • Calcium channel blockers
  • Triptans
  • Others

By Distribution channel

  • Hospital pharmacies
  • Drug stores and retail pharmacies
  • Others

By Type

  • Episodic
  • Chronic

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA

Key Market Players

  • Dr. Reddy's Laboratories Ltd.
  • FRESENIUS SE & Co. KGaA (Fresenius Kabi)
  • GlaxoSmithKline plc
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Arrotex Australia Group
  • Grunenthal
  • Eli Lilly and Company
  • Novartis AG
  • Sun Pharmaceutical Industries Ltd.

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key market segments
  • 1.3. Key benefits to the stakeholders
  • 1.4. Research Methodology
    • 1.4.1. Primary research
    • 1.4.2. Secondary research
    • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Key findings
    • 3.2.1. Top impacting factors
    • 3.2.2. Top investment pockets
  • 3.3. Porter's five forces analysis
    • 3.3.1. Moderate bargaining power of suppliers
    • 3.3.2. Moderate bargaining power of buyers
    • 3.3.3. Moderate threat of substitutes
    • 3.3.4. Moderate threat of new entrants
    • 3.3.5. Moderate intensity of rivalry
  • 3.4. Market dynamics
    • 3.4.1. Drivers
      • 3.4.1.1. Rise in prevalence of cluster headache
      • 3.4.1.2. Development of novel therapeutics for treatment of cluster headache
      • 3.4.1.3. Increase in awareness about cluster headache
    • 3.4.2. Restraints
      • 3.4.2.1. Side effects associated with medications used for cluster headache
    • 3.4.3. Opportunities
      • 3.4.3.1. Growth opportunities in emerging markets
  • 3.5. COVID-19 Impact Analysis on the market

CHAPTER 4: CLUSTER HEADACHE MARKET, BY TYPE

  • 4.1. Overview
    • 4.1.1. Market size and forecast
  • 4.2. Episodic
    • 4.2.1. Key market trends, growth factors and opportunities
    • 4.2.2. Market size and forecast, by region
    • 4.2.3. Market share analysis by country
  • 4.3. Chronic
    • 4.3.1. Key market trends, growth factors and opportunities
    • 4.3.2. Market size and forecast, by region
    • 4.3.3. Market share analysis by country

CHAPTER 5: CLUSTER HEADACHE MARKET, BY DRUG CLASS

  • 5.1. Overview
    • 5.1.1. Market size and forecast
  • 5.2. Ergot derivatives
    • 5.2.1. Key market trends, growth factors and opportunities
    • 5.2.2. Market size and forecast, by region
    • 5.2.3. Market share analysis by country
  • 5.3. Calcium channel blockers
    • 5.3.1. Key market trends, growth factors and opportunities
    • 5.3.2. Market size and forecast, by region
    • 5.3.3. Market share analysis by country
  • 5.4. Triptans
    • 5.4.1. Key market trends, growth factors and opportunities
    • 5.4.2. Market size and forecast, by region
    • 5.4.3. Market share analysis by country
  • 5.5. Others
    • 5.5.1. Key market trends, growth factors and opportunities
    • 5.5.2. Market size and forecast, by region
    • 5.5.3. Market share analysis by country

CHAPTER 6: CLUSTER HEADACHE MARKET, BY DISTRIBUTION CHANNEL

  • 6.1. Overview
    • 6.1.1. Market size and forecast
  • 6.2. Hospital pharmacies
    • 6.2.1. Key market trends, growth factors and opportunities
    • 6.2.2. Market size and forecast, by region
    • 6.2.3. Market share analysis by country
  • 6.3. Drug stores and retail pharmacies
    • 6.3.1. Key market trends, growth factors and opportunities
    • 6.3.2. Market size and forecast, by region
    • 6.3.3. Market share analysis by country
  • 6.4. Others
    • 6.4.1. Key market trends, growth factors and opportunities
    • 6.4.2. Market size and forecast, by region
    • 6.4.3. Market share analysis by country

CHAPTER 7: CLUSTER HEADACHE MARKET, BY REGION

  • 7.1. Overview
    • 7.1.1. Market size and forecast By Region
  • 7.2. North America
    • 7.2.1. Key trends and opportunities
    • 7.2.2. Market size and forecast, by Type
    • 7.2.3. Market size and forecast, by Drug class
    • 7.2.4. Market size and forecast, by Distribution channel
    • 7.2.5. Market size and forecast, by country
      • 7.2.5.1. U.S.
      • 7.2.5.1.1. Key market trends, growth factors and opportunities
      • 7.2.5.1.2. Market size and forecast, by Type
      • 7.2.5.1.3. Market size and forecast, by Drug class
      • 7.2.5.1.4. Market size and forecast, by Distribution channel
      • 7.2.5.2. Canada
      • 7.2.5.2.1. Key market trends, growth factors and opportunities
      • 7.2.5.2.2. Market size and forecast, by Type
      • 7.2.5.2.3. Market size and forecast, by Drug class
      • 7.2.5.2.4. Market size and forecast, by Distribution channel
      • 7.2.5.3. Mexico
      • 7.2.5.3.1. Key market trends, growth factors and opportunities
      • 7.2.5.3.2. Market size and forecast, by Type
      • 7.2.5.3.3. Market size and forecast, by Drug class
      • 7.2.5.3.4. Market size and forecast, by Distribution channel
  • 7.3. Europe
    • 7.3.1. Key trends and opportunities
    • 7.3.2. Market size and forecast, by Type
    • 7.3.3. Market size and forecast, by Drug class
    • 7.3.4. Market size and forecast, by Distribution channel
    • 7.3.5. Market size and forecast, by country
      • 7.3.5.1. Germany
      • 7.3.5.1.1. Key market trends, growth factors and opportunities
      • 7.3.5.1.2. Market size and forecast, by Type
      • 7.3.5.1.3. Market size and forecast, by Drug class
      • 7.3.5.1.4. Market size and forecast, by Distribution channel
      • 7.3.5.2. France
      • 7.3.5.2.1. Key market trends, growth factors and opportunities
      • 7.3.5.2.2. Market size and forecast, by Type
      • 7.3.5.2.3. Market size and forecast, by Drug class
      • 7.3.5.2.4. Market size and forecast, by Distribution channel
      • 7.3.5.3. UK
      • 7.3.5.3.1. Key market trends, growth factors and opportunities
      • 7.3.5.3.2. Market size and forecast, by Type
      • 7.3.5.3.3. Market size and forecast, by Drug class
      • 7.3.5.3.4. Market size and forecast, by Distribution channel
      • 7.3.5.4. Italy
      • 7.3.5.4.1. Key market trends, growth factors and opportunities
      • 7.3.5.4.2. Market size and forecast, by Type
      • 7.3.5.4.3. Market size and forecast, by Drug class
      • 7.3.5.4.4. Market size and forecast, by Distribution channel
      • 7.3.5.5. Spain
      • 7.3.5.5.1. Key market trends, growth factors and opportunities
      • 7.3.5.5.2. Market size and forecast, by Type
      • 7.3.5.5.3. Market size and forecast, by Drug class
      • 7.3.5.5.4. Market size and forecast, by Distribution channel
      • 7.3.5.6. Rest of Europe
      • 7.3.5.6.1. Key market trends, growth factors and opportunities
      • 7.3.5.6.2. Market size and forecast, by Type
      • 7.3.5.6.3. Market size and forecast, by Drug class
      • 7.3.5.6.4. Market size and forecast, by Distribution channel
  • 7.4. Asia-Pacific
    • 7.4.1. Key trends and opportunities
    • 7.4.2. Market size and forecast, by Type
    • 7.4.3. Market size and forecast, by Drug class
    • 7.4.4. Market size and forecast, by Distribution channel
    • 7.4.5. Market size and forecast, by country
      • 7.4.5.1. Japan
      • 7.4.5.1.1. Key market trends, growth factors and opportunities
      • 7.4.5.1.2. Market size and forecast, by Type
      • 7.4.5.1.3. Market size and forecast, by Drug class
      • 7.4.5.1.4. Market size and forecast, by Distribution channel
      • 7.4.5.2. China
      • 7.4.5.2.1. Key market trends, growth factors and opportunities
      • 7.4.5.2.2. Market size and forecast, by Type
      • 7.4.5.2.3. Market size and forecast, by Drug class
      • 7.4.5.2.4. Market size and forecast, by Distribution channel
      • 7.4.5.3. India
      • 7.4.5.3.1. Key market trends, growth factors and opportunities
      • 7.4.5.3.2. Market size and forecast, by Type
      • 7.4.5.3.3. Market size and forecast, by Drug class
      • 7.4.5.3.4. Market size and forecast, by Distribution channel
      • 7.4.5.4. Australia
      • 7.4.5.4.1. Key market trends, growth factors and opportunities
      • 7.4.5.4.2. Market size and forecast, by Type
      • 7.4.5.4.3. Market size and forecast, by Drug class
      • 7.4.5.4.4. Market size and forecast, by Distribution channel
      • 7.4.5.5. South Korea
      • 7.4.5.5.1. Key market trends, growth factors and opportunities
      • 7.4.5.5.2. Market size and forecast, by Type
      • 7.4.5.5.3. Market size and forecast, by Drug class
      • 7.4.5.5.4. Market size and forecast, by Distribution channel
      • 7.4.5.6. Rest of Asia-Pacific
      • 7.4.5.6.1. Key market trends, growth factors and opportunities
      • 7.4.5.6.2. Market size and forecast, by Type
      • 7.4.5.6.3. Market size and forecast, by Drug class
      • 7.4.5.6.4. Market size and forecast, by Distribution channel
  • 7.5. LAMEA
    • 7.5.1. Key trends and opportunities
    • 7.5.2. Market size and forecast, by Type
    • 7.5.3. Market size and forecast, by Drug class
    • 7.5.4. Market size and forecast, by Distribution channel
    • 7.5.5. Market size and forecast, by country
      • 7.5.5.1. Brazil
      • 7.5.5.1.1. Key market trends, growth factors and opportunities
      • 7.5.5.1.2. Market size and forecast, by Type
      • 7.5.5.1.3. Market size and forecast, by Drug class
      • 7.5.5.1.4. Market size and forecast, by Distribution channel
      • 7.5.5.2. Saudi Arabia
      • 7.5.5.2.1. Key market trends, growth factors and opportunities
      • 7.5.5.2.2. Market size and forecast, by Type
      • 7.5.5.2.3. Market size and forecast, by Drug class
      • 7.5.5.2.4. Market size and forecast, by Distribution channel
      • 7.5.5.3. South Africa
      • 7.5.5.3.1. Key market trends, growth factors and opportunities
      • 7.5.5.3.2. Market size and forecast, by Type
      • 7.5.5.3.3. Market size and forecast, by Drug class
      • 7.5.5.3.4. Market size and forecast, by Distribution channel
      • 7.5.5.4. Rest of LAMEA
      • 7.5.5.4.1. Key market trends, growth factors and opportunities
      • 7.5.5.4.2. Market size and forecast, by Type
      • 7.5.5.4.3. Market size and forecast, by Drug class
      • 7.5.5.4.4. Market size and forecast, by Distribution channel

CHAPTER 8: COMPETITIVE LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top winning strategies
  • 8.3. Product Mapping of Top 10 Player
  • 8.4. Competitive Dashboard
  • 8.5. Competitive Heatmap
  • 8.6. Top player positioning, 2021

CHAPTER 9: COMPANY PROFILES

  • 9.1. Dr. Reddy's Laboratories Ltd.
    • 9.1.1. Company overview
    • 9.1.2. Key Executives
    • 9.1.3. Company snapshot
    • 9.1.4. Operating business segments
    • 9.1.5. Product portfolio
    • 9.1.6. Business performance
  • 9.2. Eli Lilly and Company
    • 9.2.1. Company overview
    • 9.2.2. Key Executives
    • 9.2.3. Company snapshot
    • 9.2.4. Operating business segments
    • 9.2.5. Product portfolio
    • 9.2.6. Business performance
    • 9.2.7. Key strategic moves and developments
  • 9.3. FRESENIUS SE & Co. KGaA (Fresenius Kabi)
    • 9.3.1. Company overview
    • 9.3.2. Key Executives
    • 9.3.3. Company snapshot
    • 9.3.4. Operating business segments
    • 9.3.5. Product portfolio
    • 9.3.6. Business performance
  • 9.4. GlaxoSmithKline plc
    • 9.4.1. Company overview
    • 9.4.2. Key Executives
    • 9.4.3. Company snapshot
    • 9.4.4. Operating business segments
    • 9.4.5. Product portfolio
    • 9.4.6. Business performance
  • 9.5. Novartis AG
    • 9.5.1. Company overview
    • 9.5.2. Key Executives
    • 9.5.3. Company snapshot
    • 9.5.4. Operating business segments
    • 9.5.5. Product portfolio
    • 9.5.6. Business performance
  • 9.6. Pfizer Inc.
    • 9.6.1. Company overview
    • 9.6.2. Key Executives
    • 9.6.3. Company snapshot
    • 9.6.4. Operating business segments
    • 9.6.5. Product portfolio
    • 9.6.6. Business performance
  • 9.7. Sun Pharmaceutical Industries Ltd.
    • 9.7.1. Company overview
    • 9.7.2. Key Executives
    • 9.7.3. Company snapshot
    • 9.7.4. Operating business segments
    • 9.7.5. Product portfolio
    • 9.7.6. Business performance
  • 9.8. Teva Pharmaceutical Industries Ltd.
    • 9.8.1. Company overview
    • 9.8.2. Key Executives
    • 9.8.3. Company snapshot
    • 9.8.4. Operating business segments
    • 9.8.5. Product portfolio
    • 9.8.6. Business performance
  • 9.9. Arrotex Australia Group
    • 9.9.1. Company overview
    • 9.9.2. Key Executives
    • 9.9.3. Company snapshot
    • 9.9.4. Operating business segments
    • 9.9.5. Product portfolio
    • 9.9.6. Key strategic moves and developments
  • 9.10. Grunenthal
    • 9.10.1. Company overview
    • 9.10.2. Key Executives
    • 9.10.3. Company snapshot
    • 9.10.4. Operating business segments
    • 9.10.5. Product portfolio
    • 9.10.6. Business performance